A Phase 4 interventional study of Dex-methylphenidate hydrochloride extended-release (Focalin XR) and Placebo in Attention Deficit Hyperactivity Disorder, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2012-04-27.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis — none open to participants now, none under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Novartis.
Among the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis, this one is the 10th largest by enrollment, is one of 2 that started in 2007, is one of 2 in phase 4, and was the 7th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →None of the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis is open now. The open studies under Attention Deficit Disorder with Hyperactivity, anywhere →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 146 across the 10 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mg capsule orally once a day for 7 days
Drug: Dex-methylphenidate hydrochloride extended-release (Focalin XR)
orally once a day for 7 days
Drug: Placebo
20 mg capsule orally once a day for 7 days
Also known as: Focalin XR
orally once a day for 7 days
Change From Pre-dose (0 hr [Hour]) on the Swanson, Kotkin, Agler, M-Flynn & Pelham (SKAMP) Rating Scale Combined Score at 0.5 Hour During the 8- Hour Laboratory Classroom Day
SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.
Time frame: 0 hr and 0.5 hr post-dose
Change From Pre-dose (0 hr) in SKAMP Combined Score at All Times Excluding the 0.5 Hour Timepoint (Hours 1, 2, 4, 6, 8)
SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.
Time frame: 0, 1, 2, 4, 6, and 8 hr
Change From Pre-dose in SKAMP Attention Score at All Timepoints (0.5, 1, 2, 4, 6, 8)
SKAMP attention sub-scale is comprised of 7 questions evaluating concentration in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42.
Time frame: 0, 0.5, 1, 2, 4, 6, and 8 hours
Change From Pre-dose in SKAMP Deportment Score
SKAMP deportment sub-scale is comprised of 6 questions on behavior in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36.
Time frame: 0, 0.5, 1, 2, 4, 6 and 8 hours
Change From Pre-dose (0 hr.) in Permanent Product Measure of Performance (PERMP) Math Test-Attempted Scores at All Timepoints (0.5, 1, 2, 4, 6, 8)
Number of math questions attempted within a 10 minute period.
Time frame: 0, 0.5, 1, 2, 4, 6 and 8 hours
Change From Pre-dose in Number of Math Questions Answered Correctly on the Permanent Product Measure of Performance (PERMP) Math Test
Number of math questions answered correctly within a 10 minute period.
Time frame: 0, 0.5, 1, 2, 4, 6 and 8 hours
| Milestone | Dex-methylphenidate Hydrochloride (Focalin XR) Then Placebo | Placebo Then Dex-methylphenidate Hydrochloride (Focalin XR) |
|---|---|---|
| Started | 44 | 42 |
| Completed | 44 | 42 |
| Not completed | 0 | 0 |
| Milestone | Dex-methylphenidate Hydrochloride (Focalin XR) Then Placebo | Placebo Then Dex-methylphenidate Hydrochloride (Focalin XR) |
|---|---|---|
| Started | 44 | 42 |
| Completed | 44 | 42 |
| Not completed | 0 | 0 |
SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.
| score on a scale | Dex-methylphenidate Hydrochloride (Focalin XR) | Placebo |
|---|---|---|
| 1 hour | -6.358 ± 0.993 | 5.670 ± 0.991 |
| 2 hours | -11.573 ± 0.856 | 5.467 ± 0.854 |
| 4 hours | -11.395 ± 0.847 | 3.925 ± 0.844 |
| 6 hours | -10.622 ± 0.950 | 5.346 ± 0.952 |
| 8 hours | -10.260 ± 0.988 | 3.621 ± 0.986 |
SKAMP attention sub-scale is comprised of 7 questions evaluating concentration in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42.
| score on a scale | Dex-methylphenidate Hydrochloride (Focalin XR) | Placebo |
|---|---|---|
| 0.5 hour | -0.825 ± 0.524 | 0.862 ± 0.520 |
| 1 hour | -4.208 ± 0.589 | 2.304 ± 0.584 |
| 2 hours | -6.591 ± 0.507 | 2.465 ± 0.504 |
| 4 hours | -6.722 ± 0.506 | 1.183 ± 0.503 |
| 6 hours | -5.819 ± 0.582 | 2.715 ± 0.580 |
| 8 hours | -6.061 ± 0.584 | 1.415 ± 0.580 |
SKAMP deportment sub-scale is comprised of 6 questions on behavior in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36.
| score on a scale | Dex-methylphenidate Hydrochloride (Focalin XR) | Placebo |
|---|---|---|
| 0.5 hour | 0.127 ± 0.550 | 2.226 ± 0.550 |
| 1 hour | -1.863 ± 0.564 | 3.103 ± 0.564 |
| 2 hours | -4.850 ± 0.499 | 2.881 ± 0.499 |
| 4 hours | -4.420 ± 0.526 | 2.511 ± 0.526 |
| 6 hours | -4.614 ± 0.541 | 2.393 ± 0.541 |
| 8 hours | -3.939 ± 0.560 | 1.969 ± 0.560 |
Number of math questions attempted within a 10 minute period.
| questions attempted | Dex-methylphenidate Hydrochloride (Focalin XR) | Placebo |
|---|---|---|
| 0.5 hour | 6.93 ± 2.96 | -4.74 ± 2.96 |
| 1 hour | 33.26 ± 3.66 | -12.18 ± 3.66 |
| 2 hours | 45.52 ± 3.61 | -10.19 ± 3.61 |
| 4 hours | 45.01 ± 3.60 | -7.42 ± 3.60 |
| 6 hours | 37.33 ± 3.82 | -16.70 ± 3.84 |
| 8 hours | 44.04 ± 3.50 | -10.08 ± 3.50 |
Number of math questions answered correctly within a 10 minute period.
| questions correct | Dex-methylphenidate Hydrochloride (Focalin XR) | Placebo |
|---|---|---|
| 0.5 hour | 7.10 ± 2.72 | -5.96 ± 2.72 |
| 1 hour | 31.10 ± 3.34 | -13.21 ± 3.34 |
| 2 hours | 44.92 ± 3.44 | -11.09 ± 3.44 |
| 4 hours | 43.64 ± 3.37 | -7.52 ± 3.37 |
| 6 hours | 37.78 ± 3.55 | -16.90 ± 3.57 |
| 8 hours | 43.37 ± 3.40 | -11.44 ± 3.40 |
SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.
| score on a scale | Dex-methylphenidate Hydrochloride (Focalin XR) | Placebo |
|---|---|---|
| Change From Pre-dose (0 hr [Hour]) on the Swanson, Kotkin, Agler, M-Flynn & Pelham (SKAMP) Rating Scale Combined Score at 0.5 Hour During the 8- Hour Laboratory Classroom Day | -0.969 ± 0.909 | 3.336 ± 0.907 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dex-methylphenidate Hydrochloride (Focalin XR) | — | 0/86 (0%) | 0/86 (0%) |
| Placebo | — | 0/86 (0%) | 0/86 (0%) |
| Age Continuous(years) | Dex-methylphenidate Hydrochloride (Focalin XR) Then Placebo | Placebo Then Dex-methylphenidate Hydrochloride (Focalin XR) | Total |
|---|---|---|---|
| Mean | 9.5 ± 2.0 | 9.4 ± 1.4 | 9.5 ± 1.7 |
| Sex: Female, Male(Participants) | Dex-methylphenidate Hydrochloride (Focalin XR) Then Placebo | Placebo Then Dex-methylphenidate Hydrochloride (Focalin XR) | Total |
|---|---|---|---|
| Female | 16 | 17 | 33 |
| Male | 28 | 25 | 53 |
The record gives a start of Oct 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmethylphenidate
Attention Deficit Disorder with Hyperactivity →